MCRB Seres Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1609809 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY505.4%
TTM net income YoY-970.5%
TTM EPS YoY-1,766.7%
Revenue 3-yr CAGR-74.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,656.9%
Net margin-2,209.6%
FCF margin-3,010.4%
EBITDA margin-3,521.1%
Returns
ROE-144.3%
ROA-44.9%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.65x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio16.2%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $789,000 | $0 | $0 | $7.13M | $144.93M |
| R&D expense | $49.06M | $64.60M | $117.60M | $109.65M | $141.89M |
| SG&A expense | $39.16M | $53.18M | $77.50M | $70.26M | $69.26M |
| Operating income | -$93.97M | -$121.31M | -$195.10M | -$179.91M | -$64.49M |
| Interest expense | $0 | $0 | $2.47M | $6.02M | $2.91M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $5.70M | $136,000 | -$113.72M | -$250.16M | -$65.58M |
| EBITDA | -$89.84M | -$115.85M | -$188.85M | -$173.28M | -$58.55M |
| EPS (basic) | 0.64 | 0.00 | -17.77 | -2.31 | -0.72 |
| EPS (diluted) | 0.64 | 0.00 | -17.77 | -2.31 | -0.72 |
| Weighted avg. shares (diluted) | 8.87M | 7.77M | 6.40M | 108.08M | 91.70M |
| Balance sheet | |||||
| Cash & equivalents | $45.77M | $39.46M | $136.15M | $171.22M | $188.00M |
| Short-term investments | — | — | $0 | $18.31M | $110.70M |
| Receivables | $157,000 | $0 | — | — | — |
| Inventory | — | — | $29.65M | $0 | — |
| Current assets | $49.38M | $38.67M | $175.41M | $194.76M | $303.63M |
| PP&E, net | $7.63M | $11.53M | $17.61M | $22.98M | $17.94M |
| Total assets | $138.19M | $139.81M | $358.60M | $348.78M | $354.86M |
| Current liabilities | $19.32M | $41.22M | $98.66M | $85.60M | $82.26M |
| Long-term debt | — | — | $110.00M | $50.00M | $24.05M |
| Total debt | — | — | $110.00M | $50.00M | $24.05M |
| Total liabilities | $93.97M | $126.03M | $403.46M | $338.00M | $223.35M |
| Shareholders' equity | $44.22M | $13.78M | -$44.86M | $10.78M | $131.51M |
| Net debt | — | — | -$26.15M | -$121.22M | -$163.95M |
| Shares outstanding | 9.56M | 8.65M | 135.04M | 125.22M | 91.89M |
| Cash flow statement | |||||
| Operating cash flow | $1.12M | -$148.61M | -$117.35M | -$228.82M | $6.69M |
| Capital expenditure | $252,000 | $380,000 | $7.97M | $9.82M | $9.57M |
| Free cash flow | $865,000 | -$148.99M | -$125.33M | -$238.64M | -$2.88M |
| Investing cash flow | -$42,000 | $142.29M | $10.58M | $82.43M | $64.09M |
| Financing cash flow | $13.90M | -$90.37M | $71.70M | $129.60M | $1.18M |
| Depreciation & amortization | $4.13M | $5.47M | $6.24M | $6.63M | $5.95M |
| Stock-based compensation | $10.84M | $20.97M | $34.10M | $25.48M | $20.22M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.